CCR7 and hematopoietic and lymphoid system neoplasm: Taken together, there is ample data on target expression and mechanistic rationales as well as sufficient proof of principle and feasibility data that strongly encourage the therapeutic application of anti-CCR7 therapies in blood cancers.